Latest News From Pharmachem
06 June, 2013
A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according to new Northwestern Medicine research. In MS, the immune system attacks and destroys myelin, the insulating layer that forms around nerves in the spinal cord, brain and optic nerve. When the insulation is destroyed, electrical signals can't be effectively conducted, resulting in symptoms that range from mild limb numbness to paralysis or blindness.
12 June, 2013
The aim of this event is to give people wishing to enter the Pharmaceutical/Chemical/Medical Device sector the opportunity to meet professionals from the industry and to hear the types of skills required in today's climate. There will be a number of career coaches, industry professionals and recruitment agencies available to speak to on the night and 1 hour training overviews on " Conversion to the Pharmaceutical and Medical Device Sector and Communication/Interview Skills - Selling yourself at your best" so even if you are unsure as to what path you want to take but would like a bit of advice please feel free to come along. We will have people there from Novartis, Merck Millipore, Gilead Sciences, Sanmina, Pfizer, DePuy, Cara Partners and FMC so it is a great opportunity to network and "get your foot in the door". Agenda. Please book on line: http://www.pharmachemskillnet.ie/index.cfm?page=viewEvent&id=424